By Dr Adam Jacob Bryant

Conference Papers

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, pp. S73 - S73

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, pp. S196 - S196

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998-2008', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, pp. 1772 - 1772, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011

Back to profile page